PI3K

Faeth’s data power oral combo forward in cancer targeted by ADCs

Phase 2 data cleared the efficacy bar, emboldening Faeth to push ahead with efforts to establish the oral therapy in a field dominated by injectables.

Nick Paul Taylor Nov 9, 2026 7:00am

Merck KGaA spinout iOnctura touts PI3K inhibitor in eye cancer

Oct 14, 2026 1:42pm

A nostalgic steam train travels through a snowy winter forest in Geesthacht Germany

Relay ‘full steam ahead’ on PI3K drug after rare disease readout

May 19, 2026 6:00am

Businessman climbing steps to pluck a star from the sky

Celcuity’s gedatolisib beats Novartis’ Piqray in phase 3 study

May 4, 2026 8:06am

Sensei steps back from brink by finding Faeth merger

Feb 18, 2026 10:33am

illustration of venture capital investment funding

Incyte vets raise $102M to create better PARP, PI3K drugs

Jan 24, 2024 8:38am